Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808560 · ClinicalTrials.gov registry record · NA
Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
A NA study, sponsored by TearScience.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT01808560: Completed NA study, sponsored by TearScience.
NCT01808560 is a NA study that has completed, run by TearScience. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01808560, a NA study, has completed, sponsored by TearScience.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract surgery.
Primary Outcome
The primary endpoint is the mean change in total meibomian gland score in the Pre-treatment group compared to the Untreated group from Baseline after cataract surgery. Meibomian gland assessment was performed to evaluate the function of the meibomian glands based on the secretion characteristics from the gland orifices along the lower eyelid. Under a slit-lamp biomicrosope, the gland orifices were evaluated using a handheld instrument, Meibomian Gland Evaluator. This instrument provided a stand
Interventions
- DEVICE LipiFlow Pre-Treatment
- DEVICE LipiFlow Post-treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-01 |
| Phase | NA |
What the finished NCT01808560 record still lists
NCT01808560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which LipiFlow Pre-Treatment is the first listed.
NCT01808560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01808560 about?
NCT01808560 is a clinical study titled "Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery". The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract surgery.
What is the current status of trial NCT01808560?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2013-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01808560?
The interventions under investigation include: LipiFlow Pre-Treatment (DEVICE), LipiFlow Post-treatment (DEVICE).
Who is sponsoring clinical trial NCT01808560?
This trial is sponsored by TearScience, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01808560's enrollment target sits among peer trials
34 1570th of 2000 higher than 427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia